SG11201804669YA - (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth. - Google Patents
(r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth.Info
- Publication number
- SG11201804669YA SG11201804669YA SG11201804669YA SG11201804669YA SG11201804669YA SG 11201804669Y A SG11201804669Y A SG 11201804669YA SG 11201804669Y A SG11201804669Y A SG 11201804669YA SG 11201804669Y A SG11201804669Y A SG 11201804669YA SG 11201804669Y A SG11201804669Y A SG 11201804669YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- carbidopa
- steroid
- immune
- tumour growth
- Prior art date
Links
- TZFNLOMSOLWIDK-SNVBAGLBSA-N (2r)-2-(aminoazaniumyl)-3-(3,4-dihydroxyphenyl)-2-methylpropanoate Chemical compound NN[C@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-SNVBAGLBSA-N 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 208000026278 immune system disease Diseases 0.000 title abstract 3
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 230000004614 tumor growth Effects 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 101000629869 Homo sapiens Major facilitator superfamily domain-containing protein 1 Proteins 0.000 abstract 3
- 102100026235 Major facilitator superfamily domain-containing protein 1 Human genes 0.000 abstract 3
- 241000551546 Minerva Species 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 244000028344 Primula vulgaris Species 0.000 abstract 1
- 235000016311 Primula vulgaris Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/098237 Al WIPO I PCT (43) International Publication Date 15 June 2017 (15.06.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (51) International Patent Classification: A61P 35/00 (2006.01) A61P 19/02 (2006.01) A61K 31/198 (2006.01) A61K 31/573 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: PCT/GB2016/053849 (22) International Filing Date: 7 December 2016 (07.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1521541.1 7 December 2015 (07.12.2015) GB (71) Applicant: PROXIMAGEN LIMITED [GB/GB]; Min- erva Building 250, Babraham Research Campus, Cam- bridge Cambridgeshire CB22 3AT (GB). (72) Inventors: PRITCHARD, Martyn; c/o Proximagen Lim- ited, Minerva Building 250, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). RICHARD- SON, Peter; c/o Proximagen Limited, Minerva Building 250, Babraham Research Campus, Cambridge Cambridge- shire CB22 3AT (GB). (74) Agents: GILL JENNINGS & EVERY LLP et al.; The Broadgate Tower, 20 Primrose Street, London EC2A 2ES (GB). W O 20 17 /098 237 Al (54) Title: (R)-CARBIDOPA ALONE OR IN COMBINATION WITH A STEROID FOR TREATING PAIN, INFLAMMATION, AN INFLAMMATORY DISEASE, AN IMMUNE OR AUTOIMMUNE DISEASE AND TUMOUR GROWTH. (57) : The present invention relates to (R)-carbidopa and pharmaceutical compositions thereof, and to a combined prepara- tion of (R)-carbidopa and a steroid, and to the use of the same in the treatment or prevention of medical conditions such as pain, in- flammatory diseases, immune or autoimmune disorders and tumour growth.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521541.1A GB201521541D0 (en) | 2015-12-07 | 2015-12-07 | New therapeutic uses of enzyme inhibitors |
| PCT/GB2016/053849 WO2017098237A1 (en) | 2015-12-07 | 2016-12-07 | (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804669YA true SG11201804669YA (en) | 2018-06-28 |
Family
ID=55234516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804669YA SG11201804669YA (en) | 2015-12-07 | 2016-12-07 | (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180360786A1 (en) |
| EP (1) | EP3386497A1 (en) |
| JP (1) | JP2019500358A (en) |
| KR (1) | KR20180094513A (en) |
| CN (1) | CN108778264A (en) |
| AU (1) | AU2016367229A1 (en) |
| BR (1) | BR112018011422A2 (en) |
| CA (1) | CA3007776A1 (en) |
| GB (1) | GB201521541D0 (en) |
| IL (1) | IL259819A (en) |
| SG (1) | SG11201804669YA (en) |
| WO (1) | WO2017098237A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH576947A5 (en) * | 1969-12-18 | 1976-06-30 | Merck & Co Inc | |
| WO1993023023A1 (en) * | 1992-05-15 | 1993-11-25 | University Of Saskatchewan | Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis |
| AU2245695A (en) * | 1994-04-11 | 1995-10-30 | Du Pont Merck Pharmaceutical Company, The | Composition for treating neurological disorders |
| US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| DE102004039196B4 (en) * | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | New formulation for L-tryptophan |
| ES2500053T3 (en) * | 2007-03-09 | 2014-09-29 | Chelsea Therapeutics, Inc. | Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia |
| US8324280B2 (en) * | 2008-08-07 | 2012-12-04 | The University Of British Columbia | Treatment of prostate cancer with DDC inhibitor |
| US20110262502A1 (en) * | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| WO2012079072A2 (en) * | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US20160113893A1 (en) * | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015189534A1 (en) * | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
-
2015
- 2015-12-07 GB GBGB1521541.1A patent/GB201521541D0/en not_active Ceased
-
2016
- 2016-12-07 JP JP2018530769A patent/JP2019500358A/en active Pending
- 2016-12-07 US US15/781,871 patent/US20180360786A1/en not_active Abandoned
- 2016-12-07 CN CN201680078041.XA patent/CN108778264A/en active Pending
- 2016-12-07 CA CA3007776A patent/CA3007776A1/en not_active Abandoned
- 2016-12-07 EP EP16813017.7A patent/EP3386497A1/en not_active Withdrawn
- 2016-12-07 AU AU2016367229A patent/AU2016367229A1/en not_active Abandoned
- 2016-12-07 SG SG11201804669YA patent/SG11201804669YA/en unknown
- 2016-12-07 KR KR1020187019309A patent/KR20180094513A/en unknown
- 2016-12-07 WO PCT/GB2016/053849 patent/WO2017098237A1/en active Application Filing
- 2016-12-07 BR BR112018011422A patent/BR112018011422A2/en not_active Application Discontinuation
-
2018
- 2018-06-05 IL IL259819A patent/IL259819A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3007776A1 (en) | 2017-06-15 |
| US20180360786A1 (en) | 2018-12-20 |
| JP2019500358A (en) | 2019-01-10 |
| EP3386497A1 (en) | 2018-10-17 |
| AU2016367229A1 (en) | 2018-06-21 |
| BR112018011422A2 (en) | 2018-11-27 |
| WO2017098237A1 (en) | 2017-06-15 |
| CN108778264A (en) | 2018-11-09 |
| GB201521541D0 (en) | 2016-01-20 |
| KR20180094513A (en) | 2018-08-23 |
| IL259819A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201906557UA (en) | Novel stable formulation for fxia antibodies | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |